Bonaterra-Pastra, Anna
Solé, Montse
Lope-Piedrafita, Silvia
Lucas-Parra, Maria
Castellote, Laura
Marazuela, Paula
Pancorbo, Olalla
Rodríguez-Luna, David
Hernández-Guillamon, Mar
Funding for this research was provided by:
Instituto de Salud Carlos III (PI17/00275, PI17/00275, PI17/00275, PI17/00275, PI17/00275, PI17/00275, PI17/00275, PI17/00275, PI17/00275)
European Regional Development Fund
RICORS‐ICTUS‐Enfermedades Vasculares Cerebrales network funded by ISCIII (RD21/0006/0007, RD21/0006/0007, RD21/0006/0007, RD21/0006/0007, RD21/0006/0007, RD21/0006/0007, RD21/0006/0007, RD21/0006/0007, RD21/0006/0007)
European Union, Next Generation EU Funds
Agència de Gestió d'Ajuts Universitaris i de Recerca (SGR2021/0656, SGR2021/0656, SGR2021/0656, SGR2021/0656, SGR2021/0656, SGR2021/0656, SGR2021/0656, SGR2021/0656, SGR2021/0656)
Article History
Received: 29 April 2024
Accepted: 22 July 2024
First Online: 29 July 2024
Declarations
:
: All animal procedures were approved by the Ethics Committee for Animal Experimentation of Vall d’Hebron Research Institute and UAB (CEA-OH/10888/1) in compliance with Spanish legislation (RD 53/2013) and European Union Directives (86/609/EEC). The human study was approved by the local Clinical Investigation Ethical Committee (PR(AG)269/2017) and adhered to the Helsinki Declaration.
: Not applicable.
: The authors declare no competing interests.